Table 3.
OPRM1 Moderation of Daily Pain Effect on Daily Positive Affect
| Random Effects | |||||
|---|---|---|---|---|---|
| Covariance Parameter Estimates |
Subject | β | SE | Z | p |
| Intercept | ID | .53 | .12 | 4.43 | <.001 |
| Residual | ID | .32 | .02 | 20.27 | <.001 |
| Fixed Effects | |||||
| Predictor Variables | β | SE | df | t | p |
| Level 1 | |||||
| Centered Daily Pain | −.28 | .05 | 1218 | −5.18 | <.001 |
| Level 2 | |||||
| OPRM1 (asp vs. asn/asn) | .50 | .26 | 43 | 1.93 | .06 |
| Covariate | |||||
| Negative Affect | −.29 | .04 | 1218 | −7.39 | <.001 |
| Level 1 × Level 2 | |||||
| Centered Daily Pain × OPRM1 (asp vs. asn/asn) | −.32 | .13 | 1218 | −2.46 | <.05 |
Note. The results of the multilevel analysis of the cross-level interaction of OPRM1 genotype and daily pain on daily positive affect among fibromyalgia patients are presented.
asp = individuals either homozygous for the asp allele or heterozygous for the asp and asn alleles; asn/asn = individuals homozygous for the asp allele.